ストックスクリーナーアプリを入手
8.07
0.37%
-0.03
プレマーケット:
7.95
-0.12
-1.49%
Immunitybio Inc (IBRX) 最新ニュース
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - GlobeNewswire Inc.
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securi - GuruFocus
ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Caledonian Record
ImmunityBio, Inc. (IBRX) Class Action Lawsuit: Investors Face May 26, 2026, Deadline - NewMediaWire
Best Biotech Stocks To Watch TodayApril 22nd - MarketBeat
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After FDA Allegedly Exposed Misleading Claims: Levi & Korsinsky - PR Newswire
ANKTIVA Becomes Available in Saudi Arabia, Expanding Cancer Treatment AccessImmunityBio - Oncodaily
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - GlobeNewswire Inc.
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX - FinancialContent
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Jim Cramer Suggests Waiting for Clarity on ImmunityBio Before Taking a “Hard Look” - Insider Monkey
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - ChartMill
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline - TMX Newsfile
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
IBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - PR Newswire
ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia - Benzinga
IBRX Stock Has Quadrupled This Year – And Its Breakout Cancer Drug Has Hit A New Market - Stocktwits
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit -- The Gross Law Firm - Barchart
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
ImmunityBio’s Anktiva launches commercially in Saudi Arabia - Investing.com
ImmunityBio’s Anktiva launches commercially in Saudi Arabia By Investing.com - Investing.com UK
ImmunityBio, Inc. (NASDAQ: IBRX) recently announced that its innovative drug Anktiva® has officially entered the Saudi Arabian market, offering new treatment options for local patients with bladder cancer and lung cancer. - Bitget
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership - ImmunityBio
ImmunityBio (IBRX) Is Up 12.3% After 168% Surge In Q1 2026 Preliminary RevenueWhat's Changed - simplywall.st
IBRX Stock Extends Rally: Founder Flags Fresh Bull Case For Anktiva On Breast Cancer Immune Signal - Stocktwits
ImmunityBio, Inc. (IBRX) posts strong preliminary Q1 sales on ANKTIVA momentum - MSN
Deadline Approaching for Investors of ImmunityBio, Inc. (NASDAQ: IBRX)Contact Kaplan Fox Before May 26, 2026 - NewMediaWire
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says - Law360
IBRX Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
ImmunityBio Inc stock (US45258J1025): Is its immunotherapy pipeline strong enough to unlock new upsi - AD HOC NEWS
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential - GlobeNewswire
IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
Portnoy Law Firm Announces Class Action on Behalf of ImmunityBio, Inc. Investors - GlobeNewswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with - GlobeNewswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - TMX Newsfile
ImmunityBio, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsIBRX - Lelezard
ImmunityBio Inc stock (US45258J1025): Is its cancer immunotherapy platform strong enough to unlock n - AD HOC NEWS
ImmunityBio's Legal Deadline and Record Revenue Collide - AD HOC NEWS
IBRX Founder Backs Trump’s Psychedelic Push In ‘Transforming’ Health Policy — Flags New Anktiva Breast Cancer Risk Data - Stocktwits
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
Lobbying Update: $60,000 of IMMUNITYBIO INC. lobbying was just disclosed - Quiver Quantitative
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Concorde International Group Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - NewMediaWire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc.IBRX - Morningstar
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
Deadline to Lead in Securities Class Action Against ImmunityBio - The National Law Review
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Encourages Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights - The Daily Tribune News
Deadline to Lead in Securities Class Action Against ImmunityBio, Inc. (NASDAQ: IBRX) is May 26, 2026Contact Kaplan Fox - The Globe and Mail
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses ... - Bluefield Daily Telegraph
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class - GlobeNewswire
IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost — Hagens Berman - Morningstar
Reframing ImmunityBio: The Long-Term Platform Opportunity Beyond Anktiva (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This Year - Yahoo Finance
2026-04-17 | IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:IBRX | Press Release - Stockhouse
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock DeclineInvestors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC - ACCESS Newswire
IBRX Stock Price, Quote & Chart | IMMUNITYBIO INC (NASDAQ:IBRX) - ChartMill
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure ... - Caledonian Record
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
2.53%
2.69%
大文字化:
|
ボリューム (24 時間):